Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2025-12-25 @ 9:11 PM
Study NCT ID:
NCT06319456
Status:
RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-03-13
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Sponsor:
Ascentage Pharma Group Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-07
Start Date Type:
ACTUAL
Primary Completion Date:
2027-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-13
First Submit QC Date:
None
Study First Post Date:
2024-03-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-28
Last Update Post Date:
2024-05-29
Last Update Post Date Type:
ACTUAL